ECONOMIC EVALUATION OF PNEUMOCOCCAL VACCINATION -PCV13- IN ADULTS AGED OVER 65 YEARS IN CASTILLA Y LEÓN (SPAIN)
The burden of disease for pneumonia in older adults has a major impact on health systems.
The aim of the study is to carry out an economic evaluation of the vaccination strategy against S. pneumoniae using the 13 valent pneumococcal conjugate vaccine (PCV13) in adults over 65 years
A simulated economic model has been developed in the form of a decision tree to evaluate the cost of the vaccination strategy in the population over 65 years of the health Area of Valladolid-East, versus non-vaccination, using a Monte Carlo probabilistic analysis.
Streptococcus pneumoniae annually generates 557.24 cases of pneumococcal disease in the Valladolid-Este Health Area, 506.60 episodes are pneumonic. Vaccination to the age cohort over 65 years is an efficient measure from the third year, with a cost per quality-adjusted life years (QALY) of 20,496.20 euros. The number of QALYs gained in a decade is 86.07 and the expense of 216.252.89 euros with this vaccination strategy would be avoided.
The evaluation of the different incremental costs (QALY,euros) in the years of follow-up the program of vaccination against pneumococcus in people over 65 in Castilla y León with PCV13 is cost‐effective.